[CAS NO. 1858168-59-8] Tislelizumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1858168-59-8]

Catalog

AS1019747

Brand

Arctom Scientific

CAS

1858168-59-8

DESCRIPTION [1858168-59-8]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Tislelizumab]

For research use only. We do not sell to patients.

Summary

Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05526924	University of Chicago	Head and Neck Cancer\|Head and Neck Squamous Cell Carcinoma\|Head and Neck Carcinoma\|Head and Neck Cancer Stage IV\|Head and Neck Cancers - Throat	November 1, 2022	Phase 1
NCT02660034	BeiGene\|Myriad Genetic Laboratories, Inc.	Solid Tumors	February 2, 2016	Phase 1
NCT05027100	Haibo Zhang\|Guangzhou University of Traditional Chinese Medicine	Small Cell Lung Cancer (SCLC)	September 30, 2021	Not Applicable
NCT04570410	The First Affiliated Hospital with Nanjing Medical University	Bladder Urothelial Carcinoma	October 1, 2020	Phase 2
NCT05360277	Yanhong Deng\|Sun Yat-sen University	Metastatic Colorectal Cancer	December 1, 2022	Phase 2
NCT04921995	Fudan University	Recurrent Nasopharyngeal Carcinoma\|Unresectable Nasopharyngeal Carcinoma\|Chemotherapy Effect\|Immunotherapy\|Stereotactic Body Radiation Therapy (SBRT)	April 15, 2019	Phase 2
NCT04899427	Peking Union Medical College Hospital\|Beijing Hospital\|Beijing Tongren Hospital\|Beijing Luhe Hospital\|Shanxi Province Renmin Hospital\|Henan Cancer Hospital\|Henan Province Renmin Hospital\|The Second Affiliated Hospital of Dalian Medical University\|The Forth Hospital of Hebei Medical University\|The First Hospital of Chinese Medical University\|Qilu Hospital of Shandong University\|The First Hospital of Zhengzhou University	Primary Central Nervous System Lymphoma	March 24, 2021	Phase 2
NCT04952753	Novartis Pharmaceuticals\|Novartis	Metastatic Colorectal Cancer	November 15, 2021	Phase 2
NCT04649385	BeiGene	Advanced Solid Tumor	March 4, 2021	Phase 1
NCT05596890	Guangdong Provincial People´s Hospital	Esophageal Squamous Cell Carcinoma\|Patient-reported Outcomes\|Immunotherapy	October 25, 2022	Phase 2
NCT04562311	Sun Yat-sen University	Bladder Cancer Stage IV	October 1, 2020	Phase 2
NCT04379635	BeiGene	Non Small Cell Lung Cancer	May 29, 2020	Phase 3
NCT05614453	Australia New Zealand Gynaecological Oncology Group\|BeiGene	Metastatic Cervical Cancer	December 1, 2022	Phase 2
NCT04843267	Sun Yat-sen University	Hodgkin Lymphoma\|Chemotherapy Effect	May 1, 2021	Phase 2
NCT05273814	Tianjin Medical University Cancer Institute and Hospital	Non-Small Cell Lung Cancer	August 1, 2022	Phase 1
NCT04276493	BeiGene	Breast Cancer\|Gastric Cancer\|Gastroesophageal Junction Cancer	March 26, 2020	Phase 1\|Phase 2
NCT05406466	Fudan University	Melanoma	July 15, 2022	Phase 2
NCT04890392	Wuhan Union Hospital, China	Advanced Gastric Cancer\|Advanced Gastroesophageal Junction Adenocarcinoma	January 15, 2021	Phase 2
NCT05172440	Hongqian Guo\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Neoadjuvant Therapy	December 9, 2021	Phase 2
NCT04401800	BeiGene	Hepatocellular Carcinoma\|Unresectable Hepatocellular Carcinoma\|Metastatic Hepatocellular Carcinoma	September 4, 2020	Phase 2
NCT04164199	BeiGene	Advanced Malignancies	December 19, 2019	Phase 3
NCT04730219	Tianjin Medical University Second Hospital	Muscle Invasive Bladder Cancer\|Urothelial Carcinoma	July 11, 2020	Phase 2
NCT05223088	Fujian Cancer Hospital	Immunotherapy\|Gastrict Cancer	October 31, 2021	Phase 2
NCT05024266	First Affiliated Hospital of Zhejiang University	Lung Squamous Cell Carcinoma\|Neoadjuvant Therapy\|Immunotherapy	August 1, 2021	Phase 2
NCT05502991	Henan Provincial People´s Hospital	Glioblastoma	December 11, 2022	Phase 2
NCT05435313	Fudan University	Colorectal Cancer	July 12, 2022	Phase 2
NCT04866017	BeiGene	Non Small Cell Lung Cancer	June 17, 2021	Phase 3
NCT05375734	Second Affiliated Hospital of Nanchang University	Pulmonary Pleomorphic Carcinoma\|Immunotherapy\|Tislelizumab	August 17, 2021	Phase 2
NCT05466474	Henan Cancer Hospital	Advanced Melanoma	November 30, 2022	Phase 2
NCT05343325	Fifth Affiliated Hospital, Sun Yat-Sen University\|Dongguan People´s Hospital	Head and Neck Squamous Cell Carcinoma\|Neoadjuvant Treatment	April 29, 2022	Phase 2
NCT03430843	BeiGene	Esophageal Squamous Cell Carcinoma (ESCC)	January 26, 2018	Phase 3
NCT05116085	BeiGene	Colorectal Cancer	January 26, 2022	Phase 2
NCT05310383	Lei Li\|Peking Union Medical College Hospital	Recurrent Cervical Carcinoma\|Metastatic Cervical Carcinoma\|Persistent Cervical Carcinoma\|Radiotherapy\|Immunotherapy\|Anti-programmed Cell Death Receptor 1\|Immune Checkpoint Inhibitors\|Tislelizumab\|Objective Response Rate\|Survival Outcomes	March 27, 2022	Phase 2
NCT05516589	West China Hospital	Head and Neck Squamous Cell Carcinoma	August 20, 2022	Phase 2
NCT04814069	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Head and Neck Cancer\|Radiation\|PD-1	April 1, 2021	Phase 2
NCT04948034	Fudan University	Metastatic Colorectal Cancer	August 23, 2021	Phase 2
NCT05420584	The Fourth Affiliated Hospital of Zhejiang University School of Medicine\|Second Affiliated Hospital, School of Medicine, Zhejiang University	Rectal Neoplasms	November 1, 2022	Phase 2
NCT04865705	West China Hospital	Stage III\|Non-small Cell Lung Cancer	November 10, 2020	Phase 2
NCT05319639	Fujian Cancer Hospital	Gastric Cancer Stage IV	December 2, 2022	Phase 1
NCT05542342	Grupo Español Multidisciplinar de Melanoma\|Mirati Therapeutics Inc.\|BeiGene	Uveal Melanoma	September 23, 2022	Phase 2
NCT05595590	Tianjin Medical University Cancer Institute and Hospital	Head and Neck Cancer	October 20, 2022	Phase 2
NCT04579757	Hutchmed\|BeiGene	Metastatic Solid Tumor\|Colorectal Cancer\|Neuroendocrine Tumors\|Small Cell Lung Cancer\|Gastric Cancer\|Soft Tissue Sarcoma\|Anaplastic Thyroid Cancer	March 5, 2021	Phase 1\|Phase 2
NCT05328336	Tianjin Medical University Second Hospital	Muscle Invasive Bladder Cancer Urothelial Carcinoma	November 11, 2021	Phase 2
NCT04732494	BeiGene	Esophageal Squamous Cell Carcinoma	March 31, 2021	Phase 2
NCT05485883	Tianjin Medical University Second Hospital	Advanced Kidney Cancer	July 1, 2022	Phase 2
NCT05086627	Hebei Medical University Fourth Hospital	Locally Advanced Rectal Cancer	October 15, 2022	Phase 2
NCT05176964	Fujian Medical University Union Hospital	Rectal Cancer\|Radiation Oncology	December 31, 2021
NCT04727996	Seoul National University Hospital\|BeiGene	Advanced Biliary Tract Cancer	November 1, 2020	Phase 2
NCT03209973	BeiGene	Classical Hodgkin Lymphoma	April 21, 2017	Phase 2
NCT04318080	BeiGene\|Lymphoma Study Association	Classical Hodgkin Lymphoma	August 20, 2020	Phase 2
NCT05247619	Zhejiang Cancer Hospital	Cervical Cancer	June 30, 2022	Phase 2
NCT04663035	Ming Zhao\|Sun Yat-sen University	Recurrent Hepatocellular Carcinoma	December 21, 2020	Phase 2
NCT04004221	BeiGene	Locally Advanced or Metastatic Urothelial Bladder Cancer	July 4, 2017	Phase 2
NCT04577963	Hutchison Medipharma Limited\|BeiGene\|Hutchmed	Triple Negative Breast Cancer\|Endometrial Cancer\|Solid Tumor, Unspecified, Adult\|Colorectal Cancer	August 9, 2021	Phase 1\|Phase 2
NCT05325528	Zhejiang University	Liver Metastases	April 21, 2022	Phase 2\|Phase 3
NCT05520619	Sun Yat-sen University	Esophageal Squamous Cell Carcinoma\|Locally Advanced Esophageal Squamous Cell Carcinoma	September 15, 2022	Phase 2
NCT05518994	Henan Provincial People´s Hospital	Astrocytoma of Brain	December 1, 2022	Phase 2
NCT03412773	BeiGene	Hepatocellular Carcinoma (HCC)	December 28, 2017	Phase 3
NCT05545124	Henan Cancer Hospital	Hepatocellular Carcinoma	November 2022	Phase 2
NCT04924179	Huazhong University of Science and Technology	Patients With Advanced Metastatic Colorectal Cancer	June 1, 2021	Phase 2
NCT04924413	Quanli Gao\|Henan Cancer Hospital	Malignant Melanoma	July 1, 2021	Phase 2
NCT04716634	BeiGene\|Hutchison Medipharma Limited	Advanced Solid Tumors	April 19, 2021	Phase 2
NCT05407519	Anhui Provincial Hospital\|Zhejiang Cancer Hospital\|First Affiliated Hospital Xi´an Jiaotong University\|First Affiliated Hospital of Guangxi Medical University	Hepatocellular Carcinoma	July 25, 2022	Phase 2
NCT05544929	Novartis Pharmaceuticals\|Novartis	Carcinoma, Non-Small-Cell Lung\|Cutaneous Melanoma\|Carcinoma, Renal Cell\|Carcinoma, Ovarian Epithelial\|Nasopharyngeal Carcinoma\|Carcinoma, Thymic\|Anal Cancer\|Mesothelioma\|Esophagogastric Cancer\|High Microsatellite Instability Colorectal Carcinoma\|Squamous Cell Carcinoma of Head and Neck	October 26, 2022	Phase 1
NCT05244837	Hao Long\|Sun Yat-sen University	Tislelizumab\|Safety\|Biomarker\|Chemotherapy	December 22, 2020	Phase 2
NCT05228496	Zhejiang Cancer Hospital	Lung Cancer, Small Cell	March 17, 2022	Phase 2
NCT05104801	Peking University Cancer Hospital & Institute	Melanoma	November 2021	Phase 2
NCT05527808	Jun Liu\|Guangzhou Institute of Respiratory Disease	Non Small Cell Lung Cancer	August 1, 2022	Not Applicable
NCT04047862	BeiGene	Locally Advanced and Metastatic Solid Tumors	August 26, 2019	Phase 1
NCT04771715	Peking Union Medical College Hospital	Advanced Colorectal Carcinoma	May 1, 2019
NCT05622071	UNICANCER	Hepatocellular Carcinoma by BCLC Stage	January 4, 2023	Phase 2
NCT05502250	Stichting Hemato-Oncologie voor Volwassenen Nederland\|Danish Lymphoma Group	Hodgkin Lymphoma	January 2023	Phase 2
NCT05290116	Yunfei Yuan\|Sun Yat-sen University	Intrahepatic Cholangiocarcinoma	July 21, 2022	Phase 2
NCT04921358	BeiGene	Non-Small Cell Lung Cancer (NSCLC)	July 27, 2021	Phase 3
NCT04539444	The First Affiliated Hospital of Soochow University\|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	Relapsed Non Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma	August 1, 2020	Phase 2
NCT04215978	BeiGene	Phase 1a:Advanced Solid Tumors; Phase 1b: Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)	January 30, 2020	Phase 1
NCT05536102	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Gastric Cancer	September 5, 2022	Phase 2
NCT04627012	Sun Yat-sen University\|Second Affiliated Hospital of Guangzhou Medical University	Hepatocellular Carcinoma\|Anti-PD1 Antibody\|Liver Diseases	January 1, 2018
NCT05131698	Cancer Hospital of Guangxi Medical University	Tislelizumab\|Lenvatinib\|TACE\|Advanced Unresectable Hepatocellular Carcinoma	July 1, 2021	Early Phase 1
NCT05314101	Fujian Cancer Hospital	Immunotherapy\|Colorectal Cancer	April 1, 2022	Phase 2
NCT05582278	Wen Li\|Second Affiliated Hospital of Nanchang University	Unresectable Hepatocellular Carcinoma	January 1, 2021	Phase 2
NCT05547828	The First Affiliated Hospital of Xinxiang Medical College\|BeiGene	ESCC	December 20, 2022	Phase 2
NCT04909775	Ruijin Hospital	Muscle-Invasive Bladder Carcinoma	July 2021	Phase 2
NCT05418309	Tianjin Medical University Second Hospital	High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma	December 27, 2021	Phase 2
NCT04996459	Fudan University	Hepatocellular Carcinoma	March 1, 2020
NCT05339581	RenJi Hospital	Liver Cancer\|Liver Transplant; Complications\|Hepatocellular Carcinoma\|Portal Vein Thrombosis\|Radiotherapy; Complications	May 20, 2022	Not Applicable
NCT05516914	Nanjing Leads Biolabs Co.,Ltd	Malignant Tumors	September 1, 2022	Phase 1\|Phase 2
NCT04974047	BeiGene	Resectable Esophageal Squamous Cell Carcinoma	August 17, 2021	Phase 2
NCT05142696	Novartis Pharmaceuticals\|Novartis	Extensive Stage Small Cell Lung Cancer	July 13, 2022	Phase 1
NCT05323890	Shandong Cancer Hospital and Institute	Advanced Esophageal Squamous Cell Cancer	April 20, 2022	Phase 2
NCT05211232	Sun Yat-sen University\|Cancer Hospital of Guizhou Province\|Hunan Cancer Hospital\|Wuzhou Red Cross Hospital\|The Affiliated Hospital of Guangdong Medical College	Nasopharyngeal Carcinoma	March 25, 2022	Phase 3
NCT05044871	Tongji Hospital\|Qilu Hospital of Shandong University\|Hubei Cancer Hospital\|Hunan Cancer Hospital\|Peking University Cancer Hospital & Institute\|Obstetrics and Gynecology Hospital of Zhejiang University\|Sun Yat-sen University\|Anhui Provincial Cancer Hospital\|Jilin Provincial Tumor Hospital\|First Affiliated Hospital, Sun Yat-Sen University\|Affiliated Hospital of Jiangnan University	Ovarian Cancer	January 1, 2023	Phase 2
NCT04541277	Chinese PLA General Hospital	Acute Myeloid Leukemia, in Relapsed or Refractory\|Acute Myeloid Leukemia, Elderly, Unfit\|Acute Myeloid Leukemia With Positive Minimal Residual Disease	September 1, 2020	Phase 2
NCT05291052	The First Affiliated Hospital with Nanjing Medical University	Biliary Tract Tumor	February 14, 2022	Phase 2
NCT04902261	Changhai Hospital	Recurrent Pancreatic Cancer	November 20, 2020	Phase 2
NCT05586061	Qilu Hospital of Shandong University	HER2-positive Gastric Cancer	November 1, 2022	Phase 2
NCT04282018	BeiGene	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Mantle Cell Lymphoma\|Diffuse Large B Cell Lymphoma\|Advanced Solid Tumor\|Non-small Cell Lung Cancer\|Small Cell Lung Cancer\|Metastatic Melanoma	May 25, 2020	Phase 1\|Phase 2
NCT05189457	H. Lee Moffitt Cancer Center and Research Institute\|BeiGene	Prostate Cancer\|Stage IV Prostate Cancer	December 29, 2021	Phase 2
NCT05477264	Won Seog Kim\|Samsung Medical Center	Lymphoma	September 1, 2022	Phase 2
NCT05231850	The First Affiliated Hospital of Zhengzhou University	Colon Cancer	March 1, 2022	Phase 2
NCT03941873	BeiGene	Carcinoma, Hepatocellular\|Gastric+Gastroesophageal Junction Cancer	February 28, 2019	Phase 1\|Phase 2
NCT04363801	Leap Therapeutics, Inc.\|BeiGene	Gastric Cancer\|Gastric Adenocarcinoma\|GastroEsophageal Cancer	July 29, 2020	Phase 2
NCT04782804	Fudan University	Cholangiocarcinoma, Intrahepatic	January 1, 2021	Phase 1\|Phase 2
NCT04486391	BeiGene	Classical Hodgkin Lymphoma	September 1, 2020	Phase 3
NCT04799548	Shanghai Zhongshan Hospital	Advanced Gastric Cancer	December 30, 2021	Phase 2
NCT04170283	BeiGene	B-cell Malignancies	January 21, 2020	Phase 3
NCT05267054	BeiGene	Relapsed Diffuse Large B-cell Lymphoma\|Refractory Diffuse Large B-cell Lymphoma	April 25, 2022	Phase 1\|Phase 2
NCT04834986	Tianjin Medical University Cancer Institute and Hospital	Resectable Hepatocellular Carcinoma	April 30, 2021	Phase 2
NCT04672330	RenJi Hospital	Neoadjuvant Immunotherapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma	December 1, 2020	Phase 2
NCT05394233	Sichuan Cancer Hospital and Research Institute	Non-squamous Non-small Cell Lung Cancer\|EGFR Gene Mutation	June 1, 2022	Phase 2
NCT04952597	BeiGene	Limited Stage Small Cell Lung Cancer	July 15, 2021	Phase 2
NCT05531123	Fudan University	Bladder Cancer	September 2022	Phase 2
NCT04699188	Novartis Pharmaceuticals\|Novartis	KRAS G12C Mutant Solid Tumors\|Carcinoma, Non-Small-Cell Lung\|Carcinoma, Colorectal\|Cancer of Lung\|Cancer of the Lung\|Lung Cancer\|Neoplasms, Lung\|Neoplasms, Pulmonary\|Pulmonary Cancer\|Pulmonary Neoplasms	February 24, 2021	Phase 1\|Phase 2
NCT04777162	Peking University	Gastric Cancer\|Colo-rectal Cancer	March 2021	Phase 2
NCT03924986	BeiGene	Recurrent or Metastatic Nasopharyngeal Cancer	April 18, 2019	Phase 3
NCT05588219	Yong Zhang,MD\|First Affiliated Hospital of Guangxi Medical University	Uterine Cervical Neoplasms	December 1, 2022	Phase 2
NCT04914390	Sichuan Provincial People´s Hospital	Triple-negative Breast Cancer	August 1, 2021	Phase 2
NCT05564338	BeiGene	Hepatocellular Carcinoma	December 1, 2022	Phase 3
NCT05176925	Fudan University	Non-small Cell Lung Cancer	January 10, 2021	Phase 2
NCT04310943	Zhou Chengzhi\|Guangzhou Institute of Respiratory Disease	Lung Adenocarcinoma Stage IV	April 1, 2020	Phase 2
NCT04261439	Novartis Pharmaceuticals\|Novartis	In Escalation: All Patients With Solid Tumors and Lymphoma\|In Expansion: Melanoma, Non-small Cell Lung Cancer	February 27, 2020	Phase 1
NCT05507658	Xijing Hospital	Locally Advanced Gastric Adenocarcinoma	July 18, 2022	Phase 2
NCT05519865	Chipscreen Biosciences, Ltd.	Non Small Cell Lung Cancer	October 2022	Phase 2
NCT05359406	LI XIN-XIANG\|Fudan University	Advanced Rectal Cancer\|Distal Metastasis	December 1, 2022	Phase 2
NCT05517330	West China Hospital	Head and Neck Cancer	August 20, 2022	Phase 2
NCT03957590	BeiGene	Esophageal Squamous Cell Carcinoma (ESCC)	June 12, 2019	Phase 3
NCT04813107	Jiangsu Yahong Meditech Co., Ltd aka Asieris	Muscle Invasive Bladder Cancer	December 28, 2021	Phase 1\|Phase 2
NCT04652492	Zhongda Hospital	Hepatocellular Carcinoma	October 27, 2020	Phase 2
NCT04996446	Fudan University	Liver Malignant Tumors	August 1, 2020	Phase 2
NCT05468242	Sun Yat-sen University	Stage III Non-small Cell Lung Cancer	February 1, 2022	Phase 2
NCT04985721	Peter MacCallum Cancer Centre, Australia	Cancer	February 24, 2022	Phase 2
NCT04913571	Fudan University	Triple Negative Breast Cancer	May 27, 2021	Phase 2
NCT04443543	Fudan University	Rectal Cancer	June 22, 2020	Phase 2
NCT04615143	Sun Yat-sen University	Recurrent Hepatocellular Carcinoma	December 1, 2020	Phase 2
NCT04833257	Sun Yat-sen University	Nasopharyngeal Carcinoma	April 14, 2021	Phase 2
NCT03783442	BeiGene	Esophageal Squamous Cell Carcinoma (ESCC)	December 11, 2018	Phase 3
NCT05366829	Rutgers, The State University of New Jersey\|BioGene Pharmaceutical Ltd.\|Natera, Inc.	Carcinoma, Hepatocellular\|Liver Cell Carcinoma	July 25, 2022	Phase 2
NCT05461794	BeiGene	Esophageal Squamous Cell Carcinoma	October 3, 2022	Phase 2
NCT05512351	Henan Provincial People´s Hospital	Oligodendroglioma	December 23, 2022	Phase 2
NCT05303090	Fudan University	Pancreatic Ductal Adenocarcinoma	March 31, 2022	Phase 1
NCT04271956	German CLL Study Group	Richter Transformation	February 19, 2020	Phase 2
NCT04746924	BeiGene	Non-small Cell Lung Cancer\|NSCLC	June 8, 2021	Phase 3
NCT05241132	Wei Xu\|Shanghai Changzheng Hospital	Cancer of Unknown Primary\|Bone Cancer Metastatic\|Tislelizumab\|Gene Mutation-Related Cancer\|Immune Evasion, Tumor\|Chemotherapy Effect	November 12, 2021	Phase 2
NCT05014815	BeiGene	Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)\|Nonsmall Cell Lung Cancer, Stage IV	November 16, 2021	Phase 2
NCT05058560	The First Affiliated Hospital of Zhengzhou University	NSCLC	December 1, 2021	Phase 2
NCT05479240	Fujian Cancer Hospital	Immunotherapy	September 1, 2022	Phase 2
NCT05254847	Fudan University	Biliary Tract Cancer	December 30, 2021	Phase 2
NCT04498793	Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|First Affiliated Hospital Xi´an Jiaotong University\|Wuhan Union Hospital, China\|Beijing Huanxing Cancer Hospital	HER2-negative Breast Cancer	September 2020	Phase 2
NCT03736889	BeiGene	MSI-H+dMMR Solid Tumors	September 19, 2018	Phase 2
NCT04776590	Wuhan Union Hospital, China\|BeiGene	Esophagus Cancer\|Neoadjuvant Therapy	January 28, 2021	Phase 2
NCT04068519	BeiGene	Advanced Solid Tumors	December 28, 2016	Phase 1\|Phase 2
NCT04973306	Shanghai Zhongshan Hospital\|Peking University Cancer Hospital & Institute\|Shanghai Chest Hospital\|First Affiliated Hospital of Wenzhou Medical University\|Tianjin Medical University Cancer Institute and Hospital\|Ningbo Medical Center Lihuili Hospital\|The First People´s Hospital of Changzhou\|Zhongshan Hospital, Fudan University (Xiamen Branch)\|Xuhui Central Hospital, Shanghai\|Shanghai Minhang Central Hospital\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|Zhejiang Cancer Hospital\|Sichuan Cancer Hospital and Research Institute\|Tongji Hospital\|Sun Yat-sen University\|Shanghai Fifth People´s Hospital	Esophageal Squamous Cell Carcinoma Stage II\|Esophageal Squamous Cell Carcinoma Stage III	March 2, 2022	Phase 2\|Phase 3
NCT04979663	Fudan University	Biliary Tract Carcinoma	December 1, 2020	Phase 1\|Phase 2
NCT04899414	Peking University\|Peking University Cancer Hospital & Institute	NK+T Cell Lymphoma	May 18, 2021	Phase 2
NCT05580354	Ruijin Hospital	Non-muscle-invasive Bladder Cancer	October 9, 2022	Phase 4
NCT05604560	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|BeiGene\|Syntrix Biosystems, Inc.	Pancreatic Cancer	December 2022	Phase 2
NCT05278351	Shanghai Zhongshan Hospital	Colorectal Neoplasms Malignant	June 1, 2022	Phase 2
NCT04789434	Ruijin Hospital	Lymphoma, Large B-Cell, Diffuse\|Transplantation\|Chemotherapy	July 9, 2021	Phase 3
NCT05192681	Fujian Cancer Hospital	Advanced Non-small-cell Lung Cancer	October 10, 2021	Phase 2
NCT04405674	Shanghai Chest Hospital	Non Small Cell Lung Cancer	July 15, 2020	Phase 2
NCT04837859	University of Cologne	Classical Hodgkin Lymphoma	December 2022	Phase 2
NCT05152147	Zymeworks Inc.\|BeiGene, Ltd.	Gastric Neoplasms\|Gastroesophageal Adenocarcinoma\|Esophageal Adenocarcinoma	December 2, 2021	Phase 3
NCT05582031	Translational Research in Oncology\|Bayer\|Novartis	Anal Squamous Cell Carcinoma\|Colorectal Neoplasms\|Soft Tissue Sarcoma\|Malignant Pleural Mesothelioma\|Small Cell Lung Carcinoma\|Castrate Resistant Prostate Cancer\|Neuroendocrine Carcinoma of Prostate\|Gastroenteropancreatic Neuroendocrine Neoplasm	January 31, 2023	Phase 2
NCT05299476	Chinese PLA General Hospital	Advanced Gastroesophageal Adenocarcinoma\|First-line Therapy\|PDL1 CPS < 5	April 16, 2022	Phase 2
NCT05461235	China Medical University, China	PD-1 Antibody\|DC-Cell\|NK-Cell\|Gastrointestinal Tumours	July 15, 2022	Phase 2
NCT04922047	RenJi Hospital\|BeiGene\|Huidu Shanghai Medical Sciences Ltd	Urinary Bladder Neoplasms\|Urologic Neoplasms\|Urogenital Neoplasms\|Antineoplastic Agents\|Urinary Bladder Diseases\|Tislelizumab Antineoplastic Agents, Immunological	June 2021	Phase 1\|Phase 2
NCT03419897	BeiGene	Hepatocellular Carcinoma (HCC)	April 9, 2018	Phase 2
NCT05245760	Zhonglin Hao\|BeiGene\|University of Kentucky	Esophageal Cancer\|Esophagogastric Junction Cancer	April 2022	Phase 2
NCT03745222	Celgene\|BeiGene	Carcinoma, Non-Small-Cell Lung	May 22, 2019	Phase 3
NCT04954781	Fudan University	Intrahepatic Cholangiocarcinoma	July 14, 2021	Phase 2
NCT05533892	Wan-Guang Zhang\|Chinese Cooperative Group of Liver Cancer (CCGLC)\|Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province\|M&R Pharm\|Geneplus-Beijing Co. Ltd.\|Yuce Biotechnology Co., Ltd.\|Geneis\|Simcere Pharmaceutical Co., Ltd\|BeiGene\|Haplox Biotechnology Co., Ltd.\|Tongji Hospital	Hepatocellular Carcinoma	September 1, 2022	Phase 1
NCT05445648	First Affiliated Hospital Xi´an Jiaotong University\|BeiGene	Urinary Bladder Neoplasms	October 2022	Phase 2
NCT03432598	BeiGene	Locally Advanced Lung Cancer; Metastatic Lung Cancer	August 24, 2017	Phase 2
NCT03967977	BeiGene	Urothelial Carcinoma	May 29, 2019	Phase 3
NCT04799314	Ruijin Hospital	Lymphoma, Large B-Cell, Diffuse\|Transplantation\|Chemotherapy	April 1, 2021	Phase 3
NCT05603065	First Affiliated Hospital Xi´an Jiaotong University	Esophageal Squamous Cell Carcinoma	October 10, 2022	Not Applicable
NCT05495724	Tianjin Medical University Second Hospital	Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma	July 23, 2021	Phase 2
NCT05493683	The First Affiliated Hospital with Nanjing Medical University	Colorectal Neoplasms	August 1, 2022	Phase 2
NCT05557578	Zhejiang Cancer Hospital	Intrahepatic Cholangiocarcinoma	October 2022	Phase 2
NCT03777657	BeiGene	Gastric, or Gastroesophageal Junction Adenocarcinoma	December 13, 2018	Phase 3
NCT03744468	BeiGene	Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2	November 13, 2018	Phase 1\|Phase 2
NCT05316246	Shanghai Zhongshan Hospital\|Takeda\|BeiGene	NK+T Cell Lymphoma Nos	June 1, 2022	Phase 2
NCT04981665	Zhejiang University\|First Hospital of China Medical University\|Shandong Cancer Hospital and Institute\|The Affiliated Hospital Of Southwest Medical University\|Hainan People´s Hospital\|Tianjin Third Central Hospital	Hepatocellular Carcinoma\|Adjuvant Therapy	November 8, 2021	Phase 2
NCT05394415	Jiangsu Cancer Institute & Hospital	Esophageal Squamous Cell Carcinoma\|Tislelizumab\|Chemoradiation	May 1, 2022	Phase 1\|Phase 2
NCT04294160	Novartis Pharmaceuticals\|Novartis	BRAF V600 Colorectal Cancer	July 22, 2020	Phase 1
NCT03493451	BeiGene	Peripheral T Cell Lymphoma\|PTCL\|Extranodal NK+T-cell Lymphoma\|Extranodal NK+T-cell Lymphoma, Nasal Type\|Extranodal NK T Cell Lymphoma\|Extranodal NK T Cell Lymphoma, Nasal\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Angioimmunoblastic T-Cell Lymphoma Recurrent\|Angioimmunoblastic T-Cell Lymphoma Refractory\|Peripheral T-cell Lymphoma NOS\|Peripheral T-Cell Lymphoma, Not Otherwise Specified\|Peripheral T-Cell Lymphoma Refractory\|Anaplastic Large Cell Lymphoma\|Anaplastic Large Cell Lymphoma, ALK-Positive\|Anaplastic Large Cell Lymphoma, ALK-negative\|ALK-negative Anaplastic Large Cell Lymphoma\|ALK-Positive Anaplastic Large Cell Lymphoma\|Cutaneous T-cell Lymphoma	April 13, 2018	Phase 2
NCT05400902	Binkui Li\|Sun Yat-sen University	Intrahepatic Cholangiocarcinoma	May 31, 2022	Phase 2
NCT04850157	Shanghai Zhongshan Hospital	Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	April 20, 2021	Phase 2
NCT05160727	Zhejiang Cancer Hospital	Mismatch Repair-proficient\|Colorectal Cancer Metastatic\|Microsatellite Stable	October 1, 2021	Phase 2
NCT05401279	RenJi Hospital	Urothelial Carcinoma Bladder\|PD-1 Inhibitor	June 1, 2022	Phase 2
NCT04705129	Ruijin Hospital	Primary Mediastinal Large B Cell Lymphoma\|EBV-Positive DLBCL, Nos	January 1, 2021	Phase 2
NCT05611879	Beijing Tsinghua Chang Gung Hospital	NSCLC, Stage III	November 1, 2022	Phase 2
NCT04906382	Floor Backes\|Ohio State University Comprehensive Cancer Center	Lynch Syndrome\|Recurrent Endometrial Carcinoma\|Recurrent Endometrial Clear Cell Adenocarcinoma\|Recurrent Uterine Corpus Carcinosarcoma\|Mismatch Repair Deficiency\|Recurrent Endometrial Cancer\|Metastatic Endometrial Cancer	July 1, 2021	Early Phase 1
NCT04989855	Sun Yat-sen University	Locally Advanced Rectal Cancer	August 2021	Phase 2
NCT02795182	BeiGene	Lymphoma\|Leukemia	June 29, 2016	Phase 1
NCT05286957	Song Zhao\|BeiGene\|The First Affiliated Hospital of Zhengzhou University	NSCLC, Stage I	March 20, 2022	Phase 2
NCT05303844	Fudan University	Refractory Malignant Ascites	April 2, 2022	Phase 1
NCT05057845	Fudan University	Advanced Hepatocellular Carcinoma	September 26, 2021	Phase 2
NCT05253118	Seoul National University Hospital\|Seoul National University Bundang Hospital	DLBCL	August 18, 2022	Phase 2
NCT05036798	Tianjin Medical University Cancer Institute and Hospital	Potentially Resectable Locally Advanced Malignant Tumors of Biliary System	September 17, 2021	Phase 2
NCT05359393	Fudan University	Advanced Rectal Cancer\|Liver Metastasis\|Pulmonary Metastasis\|Microsatellite Stable Colorectal Carcinoma	December 1, 2022	Phase 2
NCT05014828	BeiGene	Advanced Solid Tumor	September 18, 2021	Phase 2
NCT05494762	BeiGene	Solid Tumor	August 25, 2022	Phase 1
NCT05319574	Sun Yat-sen University	Carcinoma, Non-Small-Cell Lung	April 24, 2022	Phase 2
NCT05609370	BeiGene	Unresectable or Metastatic Microsatellite Stable+Mismatch Repair Proficient Colorectal Cancer	November 2022	Phase 1\|Phase 2
NCT04734262	Fudan University	Metastatic Breast Cancer	April 1, 2021	Phase 2
NCT05464433	Sun Yat-sen University	Extranodal Natural Killer T Cell Lymphoma	July 30, 2022	Phase 1\|Phase 2
NCT05532319	Guangxi Medical University	Liver Cancer	October 2022	Phase 2
NCT04948697	BeiGene	Advanced Hepatocellular Carcinoma	August 20, 2021	Phase 2
NCT03469557	BeiGene	Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma	July 18, 2017	Phase 2
NCT03358875	BeiGene	Non-small Cell Lung Cancer	November 30, 2017	Phase 3
NCT04693234	BeiGene	Cervical Cancer	February 15, 2021	Phase 2
NCT05448885	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Nasopharyngeal Carcinoma	September 1, 2021	Phase 2
NCT03594747	BeiGene	Non-Small Cell Lung Cancer	July 30, 2018	Phase 3
NCT04620837	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Small Cell Lung Carcinoma	November 1, 2020	Phase 2
NCT05577702	BeiGene	Non Small Cell Lung Cancer	December 2022	Phase 2
NCT04501523	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Triple-negative Breast Cancer	August 3, 2020	Phase 2
NCT05515315	Fuzhou General Hospital	Immunotherapy Esophagus Cancer	October 9, 2022	Phase 2
NCT04599777	Second Affiliated Hospital of Guangzhou Medical University	Hepatocellular Carcinoma Non-resectable	October 1, 2020	Phase 2
NCT04730232	Tianjin Medical University Second Hospital	High-Risk\|Non-Muscle Invasive Bladder Urothelial Carcinoma	December 27, 2020	Phase 2
NCT05511623	First Affiliated Hospital of Guangxi Medical University	Cervical Cancer	October 1, 2022	Phase 2
NCT05350917	The First Affiliated Hospital of Zhengzhou University\|BeiGene\|Jiangsu Hengrui Pharmaceutical Co., Ltd.\|RemeGen Co., Ltd.	HER2-positive or Mutated Advanced Colorectal Cancer	June 20, 2022	Phase 2
NCT05469061	The First Affiliated Hospital with Nanjing Medical University	Esophageal Squamous Cell Carcinoma\|Locally Advanced Carcinoma	January 1, 2022	Phase 2

Appearance

Liquid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.